EGQ0 logo

INOVIQ BST:EGQ0 Stock Report

Last Price

€0.33

Market Cap

€31.6m

7D

0%

1Y

9.9%

Updated

23 Mar, 2024

Data

Company Financials +

EGQ0 Stock Overview

INOVIQ Ltd engages in the research, development, and commercialization of diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States.

EGQ0 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

INOVIQ Ltd Competitors

Price History & Performance

Summary of all time highs, changes and price drops for INOVIQ
Historical stock prices
Current Share PriceAU$0.33
52 Week HighAU$0.56
52 Week LowAU$0.27
Beta2.2
1 Month Change-26.55%
3 Month Change-17.00%
1 Year Change9.93%
3 Year Changen/a
5 Year Changen/a
Change since IPO-50.21%

Recent News & Updates

Recent updates

Shareholder Returns

EGQ0DE HealthcareDE Market
7D0%-1.1%1.4%
1Y9.9%0.2%7.5%

Return vs Industry: EGQ0 exceeded the German Healthcare industry which returned -1.4% over the past year.

Return vs Market: EGQ0 exceeded the German Market which returned 5.5% over the past year.

Price Volatility

Is EGQ0's price volatile compared to industry and market?
EGQ0 volatility
EGQ0 Average Weekly Movement8.9%
Healthcare Industry Average Movement5.2%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.2%
10% least volatile stocks in DE Market2.4%

Stable Share Price: EGQ0's share price has been volatile over the past 3 months.

Volatility Over Time: EGQ0's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
1983n/aLeearne Hinchhttps://www.inoviq.com

INOVIQ Ltd engages in the research, development, and commercialization of diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. The company offers hTERT test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET for capturing and isolating exosomes from liquid biopsy sample. Its cancer diagnostic pipeline includes blood tests in development for ovarian, breast, and other cancers.

INOVIQ Ltd Fundamentals Summary

How do INOVIQ's earnings and revenue compare to its market cap?
EGQ0 fundamental statistics
Market cap€31.61m
Earnings (TTM)-€3.92m
Revenue (TTM)€955.15k

33.1x

P/S Ratio

-8.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EGQ0 income statement (TTM)
RevenueAU$1.58m
Cost of RevenueAU$3.26m
Gross Profit-AU$1.68m
Other ExpensesAU$4.83m
Earnings-AU$6.51m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.071
Gross Margin-105.79%
Net Profit Margin-410.78%
Debt/Equity Ratio0%

How did EGQ0 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.